Overall, the application of RAF/MEK/ERK inhibitors contributes to targeted therapy for tumors, and the effect of RAF/MEK/ERK inhibitors facilitates the understanding of RAF mutations in tumor therapy. This evidence concerns the gene RAF1 and neoplasm.